SOPHiA DDM™ for Neurology

Transforming today’s data into tomorrow’s care

pink dots icon
Analysis of multi-omics data along with clinical information has taken the front seat in deriving valuable insights for the treatment and management of many disorders of the brain and nervous system. With this in mind, we constantly strive to deliver data-driven, integrated solutions based on genomics, radiomics and biological data, to facilitate the understanding of brain tumors as well as several inherited neurological conditions (e.g., epilepsy and seizure disorders, Huntington’s disease, autism spectrum and neuromuscular disorders).
Combining advanced machine learning capabilities with dedicated decision-support functionalities, the SOPHiA DDM™ platform offers streamlined workflows to analyze genomic and radiomics data.

In addition, the platform enables knowledge sharing among its users, facilitating the data interpretation process. As a result, we support healthcare professionals with valuable insights all along the care path, thus reducing turnaround time for better outcomes.
A universal health data analytics platform for a decentralized approach to healthcare

Save time in spotting causative genomic variants

The SOPHiA DDM™ platform enables clinical researchers to quickly and confidently identify disease-causing genomic variants, supporting the characterization of brain tumors and inherited neurological conditions. We help you overcome the challenges associated with the analysis of NGS-based data through a robust and scalable workflow (from FASTQ file to report) that adapts to the sample type, sequencer, enrichment kit, and chemistry used in your lab. Our easy-to-use SOPHiA DDM™ analytical platform equips you to efficiently manage large datasets and streamline the variant interpretation process, paving the way for a truly evidence-based care.
A universal health data analytics platform for a decentralized approach to healthcare
A universal health data analytics platform for a decentralized approach to healthcare

Unlock the hidden meaning of your imaging

SOPHiA DDM™ provides streamlined, end-to-end, automated workflows to segment medical images, extract standardized radiomics features and correlate them with outcomes. Leveraging on machine learning algorithms, the platform offers accurate analytical results, improving disease characterization supporting prognosis evaluation, therapeutic strategy decision, and response assessment in brain tumors. In addition, we are paving the way for advanced imaging analytics incorporation into future clinical trials and patient management in neuro-oncology. For example, the platform has been successfully adopted in a multi-centric research project1 to develop new evaluation criteria of treatment response in clinical trials for high-grade meningiomas, potentially redefining today's gold standards.
1Thomas Graillon, Loic Ferrer, Jason Siffre, Marc Sanson, Matthieu Peyre, Hadrien Peyrière, Grégory Mougel, Didier Autran, Emeline Tabouret, Dominique Figarella-Branger, Anne Barlier, Michel Kalamarides, Henry Dufour, Thierry Colin, Olivier Chinot, Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study, Neuro-Oncology, Volume 23, Issue 7, July 2021, Pages 1139–1147,

Delivering deep, impactful insights to BioPharma

Leverage our broad real-world genomic database and AI driven analytics to support your clinical development strategy and:
  • gain insights into biomarker testing practices
  • streamline biomarker driven clinical trial enrollment
  • accelerate drug development process
A universal health data analytics platform for a decentralized approach to healthcare

Our approach to Neurological Disorders

oncology image 3


Covers the entire care path


Allows experts to share knowledge in real time


Reaches high analytical performance*


Offers a scalable, decentralized model
pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.